In February 2025, Greek-Bulgarian swimmer Kristian Gkolomeev stepped onto the blocks at the Greensboro Aquatic Center and did something no human had ever done. He swam 50 meters in 20.89 seconds, breaking a record that had stood for 16 years. He did it under the supervision of the Enhanced Gamesˇ independent medical commission. And he did it with peptides.
That word still makes some people nervous. It shouldnˇt. The FDA has approved approximately 100 peptide-based drugs since insulin was first isolated in 1921. Two peptide drugs alone, semaglutide and tirzepatide, generated a combined $69.5 billion in revenue in 2025, making tirzepatide the best-selling drug on the planet. There are more than 650 peptide candidates in active clinical development right now. This is not fringe science. This is not a trend. This is one of the fastest-growing drug classes in the history of medicine, and the acceleration is just beginning.

Yet for something this significant, the public conversation around peptides remains surprisingly shallow. Most guides on the internet open with ˝Peptides are short chains of amino acids˛ and then list compounds without context, without evidence levels, and without telling you what we actually know versus what we are still figuring out.

This guide is different. It is built on primary research: peer-reviewed clinical trials, FDA filings, and verified data. It distinguishes between compounds backed by large-scale human trials and those still building their evidence base in preclinical research. It tells you exactly where the science stands for each compound, so you can make informed decisions with your physician rather than guessing from marketing copy.

And it is written from a position we believe matters: the intersection of elite sport, clinical science, and the emerging community of people who take human performance seriously enough to demand real evidence before they act.

By The Numbers

why Peptides, Why Now

Three forces are converging to make peptides the most important pharmacological category of the next decade.

the science matured

For most of the 20th century, peptide therapeutics were limited by a fundamental pharmacokinetic problem: the molecules degraded too quickly to be clinically useful. Native GLP-1, the gut hormone, has a half-life of about two minutes. Native GHRH lasts even less. Engineering solutions changed everything. Albumin-binding fatty acid chains extended semaglutideˇs half-life to seven days. Drug Affinity Complex technology pushed CJC-1295 to six to eight days. Novo Nordiskˇs absorption-enhancer technology made oral semaglutide possible, and in January 2026, the oral formulation of Wegovy launched in the United States. In March 2026, Johnson & Johnson received FDA approval for icotrokinra, the first targeted oral peptide that blocks the IL-23 receptor, approved for plaque psoriasis. The delivery problem that constrained peptides for decades is being solved, and the solutions are arriving faster than most observers expected.

the evidence become undeniable

The SELECT trial did not just show that semaglutide causes weight loss. It demonstrated a 20% reduction in major adverse cardiovascular events across 17,604 patients over 40 months. That is the kind of outcomes data that changes clinical practice at scale. Tirzepatideˇs SURMOUNT program showed 20.9% mean weight loss at the highest dose. And in December 2025, Eli Lilly reported Phase 3 results for retatrutide, a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, showing 28.7% mean body weight reduction at 68 weeks. Seven additional Phase 3 trials are expected to report in 2026. The data is not slowing down.
It is accelerating.

The regulatory environment shifted

In February 2026, the Department of Health and Human Services announced plans to reclassify 14 peptides previously restricted from compounding, with the stated goal of restoring their availability through licensed pharmacies under physician prescription. As of this writing, formal FDA reclassification has not been officially published, but the announced intent covers compounds including BPC-157, thymosin beta-4, CJC-1295, ipamorelin, thymosin alpha-1, MOTS-c, and GHK-Cu. At the same time, the FDA approved its first mitochondria-targeted peptide (elamipretide, September 2025) and continues to approve two to four new peptide drugs annually. The direction is unmistakable: peptides are becoming a recognized, regulated, and rapidly expanding therapeutic class.

These three forces together explain why we are not at the beginning of a trend. We are at an inflection point. The science, the evidence, and the regulatory infrastructure are aligning for the first time, and the result will reshape how we think about performance, recovery, metabolic health, and aging.